Literature DB >> 25918153

Dominance of IMP-4-producing enterobacter cloacae among carbapenemase-producing Enterobacteriaceae in Australia.

Hanna E Sidjabat1, Nicola Townell2, Graeme R Nimmo2, Narelle M George2, Jennifer Robson3, Renu Vohra4, Louise Davis5, Claire Heney2, David L Paterson6.   

Abstract

The prevalence of carbapenemase-producing Enterobacteriaceae (CPE) has been increasing worldwide. blaIMP has been reported to be the predominant carbapenemase-encoding gene within Enterobacteriaceae in Australia. However, there are limited data currently available on CPE from Queensland, Australia. A total of 58 CPE isolates were isolated between July 2009 and March 2014 from Queensland hospitals. The clonality of isolates was determined by Diversilab repetitive sequence-based PCR. The isolates were investigated for the resistance mechanisms carbapenemase, extended-spectrum β-lactamase, and AmpC β-lactamase and for aminoglycoside resistance and plasmid-mediated quinolone resistance genes by PCR. The plasmid types associated with carbapenemase-encoding genes were characterized. The majority of the CPE were Enterobacter cloacae (n = 29). The majority of Queensland CPE isolates were IMP producers and comprised 11 species (n = 48). Nine NDM-producing Enterobacteriaceae were identified. One NDM-producing Klebsiella pneumoniae isolate coproduced OXA-48. One K. pneumoniae isolate was an OXA-181 producer. The incidence of IMP producers increased significantly in 2013. blaIMP-4 was found in all IMP-producing isolates. blaTEM, qnrB, and aacA4 were common among IMP-4 producers. The HI2 (67%) and L/M (21%) replicons were associated with blaIMP-4. All HI2 plasmids were of sequence type 1 (ST1). All but one of the NDM producers possessed blaCTX-M-15. The 16S rRNA methylase genes found among NDM producers were armA, rmtB, rmtC, and rmtF. The substantial increase in the prevalence of CPE in Queensland has been associated mainly with the emergence E. cloacae strains possessing HI2 plasmids carrying blaIMP-4 over the past 2 years. The importation of NDM producers and/or OXA-48-like producers in patients also contributed to the increased emergence of CPE.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25918153      PMCID: PMC4468659          DOI: 10.1128/AAC.04378-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  43 in total

1.  When carbapenem-hydrolyzing beta-lactamase Kpc meets Escherichia coli ST131 in France.

Authors:  Thierry Naas; Gaelle Cuzon; Olivier Gaillot; René Courcol; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2011-07-18       Impact factor: 5.191

2.  Phylogenetic diversity of Escherichia coli strains producing NDM-type carbapenemases.

Authors:  S Mushtaq; S Irfan; J B Sarma; M Doumith; R Pike; J Pitout; D M Livermore; N Woodford
Journal:  J Antimicrob Chemother       Date:  2011-06-13       Impact factor: 5.790

3.  Identification of plasmids by PCR-based replicon typing.

Authors:  Alessandra Carattoli; Alessia Bertini; Laura Villa; Vincenzo Falbo; Katie L Hopkins; E John Threlfall
Journal:  J Microbiol Methods       Date:  2005-06-02       Impact factor: 2.363

4.  Characterization of multidrug-resistant Klebsiella pneumoniae from Australia carrying blaNDM-1.

Authors:  Shereen Shoma; Muhammad Kamruzzaman; Andrew N Ginn; Jonathan R Iredell; Sally R Partridge
Journal:  Diagn Microbiol Infect Dis       Date:  2013-10-22       Impact factor: 2.803

5.  Identification of plasmid-mediated extended-spectrum and AmpC beta-lactamases in Enterobacter spp. isolated from dogs.

Authors:  Hanna E Sidjabat; Nancy D Hanson; Ellen Smith-Moland; Jan M Bell; Justine S Gibson; Lucio J Filippich; Darren J Trott
Journal:  J Med Microbiol       Date:  2007-03       Impact factor: 2.472

6.  Clinical features and molecular epidemiology of CMY-type beta-lactamase-producing Escherichia coli.

Authors:  Hanna E Sidjabat; David L Paterson; Zubair A Qureshi; Jennifer M Adams-Haduch; Alexandra O'Keefe; Alvaro Pascual; Jesús Rodríguez-Baño; Yohei Doi
Journal:  Clin Infect Dis       Date:  2009-03-15       Impact factor: 9.079

7.  MLST reveals potentially high-risk international clones of Enterobacter cloacae.

Authors:  R Izdebski; A Baraniak; M Herda; J Fiett; M J M Bonten; Y Carmeli; H Goossens; W Hryniewicz; C Brun-Buisson; M Gniadkowski
Journal:  J Antimicrob Chemother       Date:  2014-09-12       Impact factor: 5.790

8.  Molecular characterization of an enterobacterial metallo beta-lactamase found in a clinical isolate of Serratia marcescens that shows imipenem resistance.

Authors:  E Osano; Y Arakawa; R Wacharotayankun; M Ohta; T Horii; H Ito; F Yoshimura; N Kato
Journal:  Antimicrob Agents Chemother       Date:  1994-01       Impact factor: 5.191

9.  Molecular epidemiology of CTX-M-producing Escherichia coli isolates at a tertiary medical center in western Pennsylvania.

Authors:  Hanna E Sidjabat; David L Paterson; Jennifer M Adams-Haduch; Lindsay Ewan; Anthony W Pasculle; Carlene A Muto; Guo-Bao Tian; Yohei Doi
Journal:  Antimicrob Agents Chemother       Date:  2009-08-17       Impact factor: 5.191

10.  Identification of Qnr and AAC(6')-1b-cr plasmid-mediated fluoroquinolone resistance determinants in multidrug-resistant Enterobacter spp. isolated from extraintestinal infections in companion animals.

Authors:  Justine S Gibson; Rowland N Cobbold; Peter Heisig; Hanna E Sidjabat; Myat T Kyaw-Tanner; Darren J Trott
Journal:  Vet Microbiol       Date:  2009-12-03       Impact factor: 3.293

View more
  32 in total

1.  Genomic Characteristics of NDM-Producing Enterobacteriaceae Isolates in Australia and Their blaNDM Genetic Contexts.

Authors:  Alexander M Wailan; David L Paterson; Karina Kennedy; Paul R Ingram; Evan Bursle; Hanna E Sidjabat
Journal:  Antimicrob Agents Chemother       Date:  2015-10-19       Impact factor: 5.191

Review 2.  Metallo-β-Lactamases: Structure, Function, Epidemiology, Treatment Options, and the Development Pipeline.

Authors:  Sara E Boyd; David M Livermore; David C Hooper; William W Hope
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

Review 3.  The Global Ascendency of OXA-48-Type Carbapenemases.

Authors:  Johann D D Pitout; Gisele Peirano; Marleen M Kock; Kathy-Anne Strydom; Yasufumi Matsumura
Journal:  Clin Microbiol Rev       Date:  2019-11-13       Impact factor: 26.132

Review 4.  The rapid spread of carbapenem-resistant Enterobacteriaceae.

Authors:  Robert F Potter; Alaric W D'Souza; Gautam Dantas
Journal:  Drug Resist Updat       Date:  2016-09-19       Impact factor: 18.500

Review 5.  Aminoglycoside Resistance: The Emergence of Acquired 16S Ribosomal RNA Methyltransferases.

Authors:  Yohei Doi; Jun-Ichi Wachino; Yoshichika Arakawa
Journal:  Infect Dis Clin North Am       Date:  2016-06       Impact factor: 5.982

Review 6.  OXA-48-like carbapenemases producing Enterobacteriaceae in different niches.

Authors:  Assia Mairi; Alix Pantel; Albert Sotto; Jean-Philippe Lavigne; Aziz Touati
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-10-08       Impact factor: 3.267

7.  Draft Genome Sequences of Two IMP-4-Producing Escherichia coli Sequence Type 131 Isolates in Australia.

Authors:  Hanna E Sidjabat; Jennifer Robson; David L Paterson
Journal:  Genome Announc       Date:  2015-08-27

8.  First Report of blaIMP-14 on a Plasmid Harboring Multiple Drug Resistance Genes in Escherichia coli Sequence Type 131.

Authors:  Nicole Stoesser; Anna E Sheppard; Gisele Peirano; Robert P Sebra; Tarah Lynch; Luke W Anson; Andrew Kasarskis; Mary R Motyl; Derrick W Crook; Johann D Pitout
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

9.  Isolation and plasmid characterization of carbapenemase (IMP-4) producing Salmonella enterica Typhimurium from cats.

Authors:  Sam Abraham; Mark O'Dea; Darren J Trott; Rebecca J Abraham; David Hughes; Stanley Pang; Genevieve McKew; Elaine Y L Cheong; John Merlino; Sugiyono Saputra; Richard Malik; Thomas Gottlieb
Journal:  Sci Rep       Date:  2016-10-21       Impact factor: 4.379

10.  Clinical management of resistance evolution in a bacterial infection: A case study.

Authors:  Robert J Woods; Andrew F Read
Journal:  Evol Med Public Health       Date:  2015-10-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.